Kufe DW, Pollock RE, Weichselbaum RR, et al., eds. Cancer Medicine. 6th ed.Hamilton, Canada: BC Decker; 2003.
4.
Gores GJ. Early detection and treatment of cholangiocarcinoma. Liver Transpl. 2000;6(6 suppl 2):530-534.
5.
Curley SA. Gastrointestinal tract 102. Gallbladder and bile duct cancer. In: Kufe DW, Pollock RE, Weichselbaum RR et al., eds. Cancer Medicine. 6th ed.Hamilton, Canada: BC Decker; 2003: Table 102-2.
6.
Thomas R, ed. The Eclectic Practice of Medicine. 2nd ed.Cincinnati, Ohio: Scudder Brothers; 1907.
7.
Wu T, Leng J, Han C, Demetris AJ. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther. 2004;3:299-307.
8.
Zhang Z, Lai GH, Sirica AE. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology. 2004;39:1028-1037.
9.
Wu GS, Zou SQ, Liu ZR, Tang ZH, Wang JH. Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World J Gastroenterol. 2003;9:1302-1306.
10.
Lai GH, Zhang Z, Sirica AE. Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol Cancer Ther. 2003;2:265-271.
11.
de Jonge M, Verweij J. The epothilone dilemma. J Clin Oncol. 2005;23:9048-9050.
12.
Ziegler D, Nowak H, Kemplert P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alphalipoic acid: a meta-analysis. Diabet Med. 2004;21:114-121.
13.
Wallace JM. Nutritional and botanical modulation of the inflammatory cascade—eicosanoids, cyclooxygenases, and lipoxygenases—as an adjunct in cancer therapy. Integr Cancer Ther. 2002;1:7-37.
14.
Jho DH, Cole SM, Lee EM, Espat NJ. Role of omega-3 fatty acid supplementation in inflammation and malignancy. Integr Cancer Ther. 2004;3:98-111.
15.
Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 2005;8:265-269.
16.
Leipner J, Saller R. Systemic enzyme therapy in oncology: effect and mode of action. Drugs. 2000;59:769-780.
17.
Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem. 1995;270:24995-25000.
18.
Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol. 2006;69:195-206.
19.
Shizhong Z, Anping C. Activation of PPAR is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem J. 2004; 384(pt 1):149-157.
20.
Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, Orlowski RZ. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res. 2002;62:3868-3875.
21.
Trump DL, Hershberger PA, Bernardi RJ, et al. Anti-tumor activity of calcitriol: preclinical and clinical studies. J Steroid Biochem Mol Biol. 2004;89-90:519-526.
22.
Beer TM, Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic. Mol Cancer Ther. 2004;3:373-381.
23.
Yen Y, Chu PG, Feng W. Paraneoplastic syndromes in cancer: case 3. Parathyroid hormone-related hypercalcemia in cholangiocarcinoma. J Clin Oncol. 2004;22:2244-2245.
24.
D’Costa DF. Cholangiocarcinoma associated with hypercalcaemia and ascites presenting as sclerosing cholangitis. Br J Clin Pract. 1994;48:217-218.
25.
Garcia-Lora A, Pedrinaci S, Garrido F. Protein bound polysaccharide K and interleukin-2 regulate different nuclear transcription factors in the NKL human natural killer cell line. Cancer Immunol Immunother. 2001;50:191-198.
26.
Fisher M, Yang LX. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res. 2002;22:1737-1754.
27.
Kelly GS. Larch arabinogalactan: clinical relevance of a novel immune-enhancing polysaccharide. Altern Med Rev. 1999; 4:96-103.
28.
Larch arabinogalactan. Altern Med Rev. 2000;5:463-466.
29.
Sanchez-Barcelo EJ, Cos S, Fernandez R, Mediavilla MD. Melatonin and mammary cancer: a short review. Endocr Relat Cancer. 2003;10:153-159.
30.
Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, Maestroni GJ. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuro Endocrinol Lett. 2001;22:45-47.
31.
Qin L, Wang X, Duan Q, Chen B, He S. Inhibitory effect of melatonin on the growth of H22 hepatocarcinoma cells by inducing apoptosis. J Huazhong Univ Sci Technolog Med Sci. 2004;24:19-21, 31-31.
32.
Yan JJ, Shen F, Wang K, Wu MC. Patients with advanced primary hepatocellular carcinoma treated by melatonin and transcatheter arterial chemoembolization: a prospective study. Hepatobiliary Pancreat Dis Int. 2002;1:183-186.
33.
Nakanuma Y, Harada K, Ishikawa A, Zen Y, Sasaki M. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2003;10:265-281.
34.
Rubin P, ed. Clinical Oncology: A Multidisciplinary Approach for Physicians and Students. 8th ed.Philadelphia, Pa: W.B. Saunders; 2001.
35.
Yano H, Mizoguchi A, Fukuda K, et al. The herbal medicine sho-saiko-to inhibits proliferation of cancer cell lines by inducing apoptosis and arrest at the G0/G1 phase. Cancer Res. 1994; 54:448-454.
36.
Fava G, Marucci L, Glaser S, et al. Gamma-aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res.2005;65:11437-11446.
37.
Okaro AC, Fennell DA, Corbo M, Davidson BR, Cotter FE. Pk11195, a mitochondrial benzodiazepine receptor antagonist, reduces apoptosis threshold in Bcl-X(L) and Mcl-1 expressing human cholangiocarcinoma cells. Gut. 2002;51:556-561.
38.
Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. John’s Wort on irinotecan metabolism. J Natl Cancer Inst. 2002;94:1247-1249.
39.
Hu Z, Yang X, Ho PC, et al. St. John’s Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. Pharm Res. 2005;22:902-914.
40.
Lowenfels AB. Does bile promote extracolonic cancer?Lancet. 1978;2:2239-2241.
41.
Yoon JH, Werneburg NW, Higuchi H, et al. Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/ Raf-1-dependent mechanism. Cancer Res. 2002;62:600-6505.
42.
Schroeder CP, Goeldner EM, Schulze-Forster K, Eickhoff CA, Holtermann P, Heidecke H. Effect of selenite combined with chemotherapeutic agents on the proliferation of human carcinoma cell lines. Biol Trace Elem Res. 2004;99:17-25.
43.
Marienfeld C, Tadlock L, Yamagiwa Y, Patel T. Inhibition of cholangiocarcinoma growth by tannic acid. Hepatology. 2003; 37:1097-1104.
44.
Pettersson F, Colston KW, Dalgleish AG. Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells. Pancreas. 2001;23:273-279.
45.
Banerjee S, Zhang Y, Ali S, et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res. 2005;65:9064-9072.
